A
Allen Lee Cohn
Researcher at University of Southern California
Publications - 147
Citations - 9289
Allen Lee Cohn is an academic researcher from University of Southern California. The author has contributed to research in topics: Bevacizumab & FOLFIRI. The author has an hindex of 35, co-authored 142 publications receiving 7270 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Andrea L. Webber,Scot Ebbinghaus,Junshui Ma,Abby B. Siegel,Ann-Lii Cheng,Masatoshi Kudo,Angela Tatiana Alistar,Jamil Asselah,Jean-Frédéric Blanc,Ivan Borbath,Timothy Cannon,Ki Chung,Allen Lee Cohn,David Cosgrove,Nevena Damjanov,Mukul Gupta,Yoshivasu Karino,Mark Karwal,Andreas Kaubisch,Robin Kate Kelley,Jena-Luc Van Laethem,Timothy Larson,James Lee,Daneng Li,Atisha Manhas,Gulam Abbas Manji,Kazushi Numata,Benjamin M. Parsons,Andrew Scott Paulson,Carmine Pinto,Robert A. Ramirez,Suresh Ratnam,Magnus Rizell,Olivier Rosmorduc,Yvonne Sada,Yutaka Sasaki,Per I Stal,Simone I. Strasser,Joerg Trojan,Gina M. Vaccaro,Hans Van Vlierberghe,Alan Weiss,Karl-Heinz Weiss,Tatsuya Yamashita +58 more
TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.
Journal ArticleDOI
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
J. Randolph Hecht,Edith P. Mitchell,Tarek Chidiac,Carroll Scroggin,Christopher Hagenstad,David R. Spigel,John Marshall,Allen Lee Cohn,David McCollum,Philip J. Stella,Robert Deeter,Seta Shahin,Rafael G. Amado +12 more
TL;DR: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS, and these combinations are not recommended for the treatment of mCRC in clinical practice.
Journal ArticleDOI
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
Josep Tabernero,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannova,György Bodoky,Rocio Garcia-Carbonero,Tudor Ciuleanu,David Craig Portnoy,Eric Van Cutsem,Axel Grothey,Jana Prausová,Pilar García-Alfonso,Kentaro Yamazaki,Philip Clingan,Sara Lonardi,Tae Won Kim,Lorinda Simms,Shao Chun Chang,F. Nasroulah +18 more
TL;DR: Ramucirumab plus F OLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma and toxic effects were manageable.
Journal ArticleDOI
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
Howard S. Hochster,Lowell L. Hart,Ramesh K. Ramanathan,Barrett H. Childs,John D. Hainsworth,Allen Lee Cohn,Lucas Wong,Louis Fehrenbacher,Yousif A. Abubakr,M. Wasif Saif,Lee S. Schwartzberg,Eric Hedrick +11 more
TL;DR: The addition of bevacizumab to oxaliplatin and fluoropyrimidine and fluoripyrimidine regimens is well tolerated as first-line treatment of mCRC and does not markedly change overall toxicity.
Journal ArticleDOI
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
Heinz-Josef Lenz,Eric Van Cutsem,Shirin Khambata-Ford,Robert J. Mayer,Philip J. Gold,Philip Stella,B. Mirtsching,Allen Lee Cohn,Andrew William Pippas,Nozar Azarnia,Zenta Tsuchihashi,David J. Mauro,Eric K. Rowinsky +12 more
TL;DR: Cetuximab is active and well tolerated in metastatic CRC refractory to irinotecan, oxaliplatin, and fluoropyrimidines and neither EGFR kinase domain mutations nor EGFR gene amplification appear to be essential for response to cetUXimab in this setting.